All data are based on the daily closing price as of August 1, 2025
c

Chugai Pharmaceutical

4519.TSE
48.77 USD
-0.39
-0.79%

Overview

Last close
48.77 usd
Market cap
80.26B usd
52 week high
59.92 usd
52 week low
29.51 usd
Target price
54.96 usd

Valuation

P/E
31.0578
Forward P/E
28.169
Price/Sales
10.2521
Price/Book Value
6.1016
Enterprise Value
73.65B usd
EV/Revenue
9.2665
EV/EBITDA
19.9478

Key financials

Revenue TTM
7.95B usd
Gross Profit TTM
5.59B usd
EBITDA TTM
3.88B usd
Earnings per Share
1.59 usd
Dividend
0.71 usd
Total assets
14.35B usd
Net debt
-2.75B usd

About

Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. It offers oncology products, such as Alecensa, Avastin, FoundationOne, Herceptin, Kadcyla, Perjeta, Polivy, Tecentriq, and Phesgo; Actemra for humanized anti-human IL-6 receptor monoclonal antibody; CellCept for immunosuppressant; Edirol, an osteoporosis agent; Enspryng, a pH-dependent binding humanized anti-IL-6 receptor monoclonal antibody; Evrysdi for spinal muscular atrophy agent; Hemlibra, an anti-coagulation factor IXa/X humanized bispecific monoclonal antibody; Mircera, an erythropoiesis-stimulating agent; PiaSky, a pH-dependent binding humanized anti-complement (C5) monoclonal antibody; Ronapreve, an anti-SARS-CoV-2 monoclonal antibody; Tamiflu, an anti-influenza agent; and Vabysmo, an anti VEGF/anti Ang-2 bispecific antibody. The company has strategic alliances and collaboration with Roche Group; research collaboration and option to license agreement with Araris Biotech AG to develop ADCs using Araris AraLinQ technology; and research and license agreement with Gero PTE. LTD. to develop novel therapies for age-related diseases. The company was formerly known as Chugai Shinyaku Shokai and changed its name to Chugai Pharmaceutical Co., Ltd. in January 1943. Chugai Pharmaceutical Co., Ltd. was founded in 1925 and is headquartered in Chuo-ku, Japan. Chugai Pharmaceutical Co., Ltd. operates as a subsidiary of Roche Holding Ltd.
  • Symbol
    4519.TSE
  • Exchange
    TSE
  • Isin
    JP3519400000
  • Country
    Japan
  • Sector
    Healthcare
  • Industry
    Drug Manufacturers - General
  • CEO
    Dr. Osamu Okuda
  • Headquarter
    Chuo
  • Web site
    https://www.chugai-pharm.co.jp
Jakota Newsletter

Stay ahead in the JAKOTA stock markets with our roundup of vital insights

Icon scroll to top